STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER: STENO
STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2021 – 30.09.2021. The report is attached to this release and is also available on https://stenocare.com/investor-relations/
Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:
During Q3 we had a “champagne moment” with the completion of the upgrade of our Danish indoor cultivation facility. This takes our cultivation capabilities to a new level of control and quality for the industry. This was an important milestone for the single largest investment into executing STENOCARE 2.0, that creates a critical asset in our supply chain.
| (KDKK) | 01.07.2021 30.09.2021 3 months | 01.07.2020 30.09.2020 3 months | 01.01.2021 30.09.2021 9 months | 01.01.2020 30.09.2020 9 months |
| Net sales | 0 | 0 | 1,890 | 93 |
| Operating profit before depreciation (EBITDA) | -3,158 | -2,492 | -8,574 | -7,985 |
| Net financial items | -16 | -134 | -106 | -1,637 |
| Investment in tangible fixed assets | 784 | 2,128 | 3,747 | 8,865 |
| Result per share (DKK) | -0.26 | -0.19 | -0.70 | -0.77 |
| Solidity (%) | 95 | 98 | 95 | 98 |
Result per share: The result for the period divided by the average number of shares. Total number of shares as of September 30, 2021, amounted to 11,676,126 (11,676,126). Average number of shares for the third quarter 2021 was 11,676,126 (11,676,126).
Solidity: Equity divided by total capital.
Highlights during the period
- August 2021 – STENOCARE announced that it has completed its scaled-up indoor cultivation facility. The facility has been constructed, upgraded and completed to meet uniquely high pharma-grade standards. This means that STENOCARE’s premium mother plants from its existing, small scale facility can now move in and the scaled up cultivation can be initiated.